CLO21-017: Hospitalization and Supportive Care Measure (SCM) Utilization in Patients With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC) in EMBRACA: Results From an Extended Follow-up Post-hoc Analysis

Authors: Sara Hurvitz MD1, Alexander Niyazov PharmD, MPH2, Ying Chen PhD3, and Hope S. Rugo MD4
View More View Less
  • 1 University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA
  • | 2 Pfizer, Inc., New York, NY
  • | 3 Pfizer, Inc., La Jolla, CA
  • | 4 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Restricted access

Funding: Pfizer Inc.

Corresponding Author: Alexander Niyazov, PharmD., MPH
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 152 152 15
PDF Downloads 134 134 10
EPUB Downloads 0 0 0